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ABSTRACT
Objective: The present study was undertaken to prolong the release of orally administered drug. The aim is to formulate, develop, and evaluate the 
intragastric buoyant tablets of venlafaxine hydrochloride, which releases the drug in a sustained manner over a period of 12 hrs. Different formulations 
were formulated using the polymers Carbopol 934 P, xanthan gum, hydroxypropyl methylcellulose (HPMC K100M) with varying concentration of 
drug: Polymer ratio of 1:1, 1:1.5, 1:2, in which sodium bicarbonate acts as gas generating agent, and microcrystalline cellulose as a diluent.
Methods: The tablets were prepared by direct compression and evaluated for tablet thickness, weight variation, tablet hardness, friability, in vitro 
buoyancy test, in vitro drug release and Fourier transform infrared spectroscopy. Formulations were evaluated by floating time, floating lag time and 
in vitro drug release. Dissolution profiles were subjected for various kinetic treatments to analyze the release pattern of drug.
Results: It was found that drug release depends on swelling, erosion, and diffusion, thus following the non-Fickian/anomalous type of diffusion. 
Formulation F8 was considered as an optimized formulation for gastro retentive floating tablet of venlafaxine hydrochloride. The optimized 
formulation showed sustained drug release and remained buoyant on the surface of the medium for more than 12 hrs. As the concentration of HPMC 
K100M increases in the formulation the drug release rate was found to be decreased. The optimized formulation was subjected for the stability studies 
and was found to be stable as no significant change was observed in various evaluated parameters of the formulation.
Conclusion: It can be concluded that floating drug delivery system of venlafaxine hydrochloride can be successfully formulated as an approach to 
increase gastric residence time, thereby improving its bioavailability.
Keywords: Venlafaxine hydrochloride, Intragastric buoyant, Floating drug delivery systems, Hydroxypropyl methyl cellulose K100M, Carbopol 934 P, 
Xanthan gum.
INTRODUCTION
Oral controlled drug delivery system is useful to maintain 
therapeutically effective plasma drug concentration levels for a 
longer duration thereby reducing the dosing frequency and to 
minimize fluctuations in the plasma drug concentration at the 
steady state by delivering the drug in a controlled and reproducible 
manner [1]. Moreover, it is easy for administration, no patient 
compliances, and flexibility in the formulation. Many studies have 
been performed concerning the sustained release dosage form of 
drug, which have aimed at the prolongation of gastric emptying 
time, i.e., gastro retentive drug delivery system, which will provide 
as with new and important therapeutic options, which utilize 
several approaches such as intragastric floating system [2], high-
density system [3], mucoadhesive system [4], and super porous-
biodegradable hydrogel systems [5]. In gastro retentive system, 
drugs can remain in the gastric region for several hours and 
significantly prolong the gastric resistance time of drugs. Prolonged 
gastric retention improves bioavailability, reduces drug waste 
and improves solubility of drugs that are less soluble in a high pH 
environment. It has applications also for long drug delivery to the 
stomach and proximal small intestines [6]. Gastro retention helps 
to provide better availability of new products with new therapeutic 
possibility and substantial benefits for patients [7]. Drugs that are 
required to be formulated into gastro-retentive dosage forms include 
drugs acting locally and primarily absorb in the stomach, drugs that 
are orally soluble at an alkaline pH, those with a narrow window of 
absorption, drugs absorbed rapidly from gastrointestinal tract (GIT) 
and drugs that degrade in colon [8].
Different methods are used depending on the mechanism of buoyancy 
in the development floating drug delivery system (FDDS). They are 
effervescent and non-effervescent system [9]. The most commonly used 
excipients in non-effervescent FDDS are gel forming on highly swellable 
cellulose type hydrocolloids, polysaccharides and matrix forming 
polymers such as polycarbonate, polyacrylate, polymethacrylate, 
and polystyrene. The floating dosage forms involve intimate mixing 
of drug with a gel forming hydrocolloid, which swells in contact 
with gastric fluid after oral administration and maintains a relative 
integrity of shape and bulk density of less than unity with in the outer 
gelatinous barrier [10]. The air trapped by the swollen polymer confers 
buoyancy to these dosage forms and gel structure act as a reservoir 
for sustained drug release [11]. The effervescent buoyant delivery 
system utilizes matrices prepared with swellable polymers such as 
Methocelor polysaccharides (chitosan) and effervescent components 
such as sodium bicarbonate and citric or tartaric acid [12] or matrices 
containing chambers of liquid that gasify at body temperature [13-15]. 
They are fabricated in such a way that on arrival in the stomach, carbon 
dioxide is liberated by the acidity of the gastric contents and entrapped 
in a gellified hydrocolloid which produces an upward movement of the 
dosage form and maintains its buoyancy.
Venlafaxine hydrochloride is a unique anti-depressant and is referred 
to as a serotonin-nor epinephrine-dopamine reuptake inhibitors [16]. 
Venlafaxine hydrochloride helps in releasing a small quantity of drug, 
advantage for treating a depressive disorder. It has a short bioavailability 
of 12.6% and biological half-life of 5 hrs. Therefore, the frequent 
administration is necessary to maintain the therapeutic concentration 
of the drug with in the therapeutic index. To overcome the drawback, 
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the present study, gastric retentive controlled release dosage form of 
the drug in the form of tablet was formulated [17] with Carbopol 934P, 
xanthan gum, and hydroxypropyl methylcellulose (HPMC K100M) with 
varying concentration of drug: Polymer ratio (1:1, 1:1.5, 1:2).
The aim of the present study was not only preparing intragastric 
buoyant tablet but also to release the drug in controlled system. 
Polymers were added in different concentrations with varying amount 
of retardant material and investigated the release profile of the drug 
by in vitro dissolution study to achieve an extended retention in the 
upper GIT, to enhance the absorption and improve the bioavailability.
MATERIALS AND METHODS
Materials
Venlafaxine hydrochloride and HPMC K100 M was procured as a gift 
sample from Aurobindo Pharma, Carbopol 934P and xanthan gum 
from Himedia Laboratories, microcrystalline cellulose and magnesium 
stearate from SD Fine Chemicals.
Methods
Preparation of venlafaxine hydrochloride floating tablets
Floating matrix tablet were prepared using direct compression 
technique [18-21] with the use of a different polymer with varying 
concentration (1:1, 1:1.5, 1:2), i.e., drug to polymer ratio as shown 
in Table 1. All polymer and drug were passed through sieve no.80 
separately. Then drug was mixed for 10 minutes with polymers and 
other excipients in weight proportion as mentioned in the table. The 
powder blend was then lubricated by magnesium stearate and talc. 
Finally, this lubricated blend was subjected to compression into tablets 
using 10-mm flat-face on a 16 stationary rotary punching tablet 
machine. The composition of all the formulations is given in Table 1.
Evaluation of powder blend
The powder blends of all formulation were evaluated for bulk density, 
tapped density [22], angle of repose [23], Carr’s compressibility 
index [24], and Hausner ratio [25].
Evaluation of tablets
The prepared intragastric buoyant tablets were subjected to weight 
variation, hardness by using Monsanto hardness tester, thickness 
using Vernier Calliper, friability using Roche friabilator and drug 
content [26,27].
Swelling index
The swelling of tablet involves the absorption of a liquid resulting in an 
increase in weight and volume. Liquid uptake by the particle may be due 
to saturation of capillary spaces within the particles. The liquid enters 
the particles through pores and bind to a large molecule, breaking 
the hydrogen bond, and resulting in the swelling of particle [28,29]. The 
extent of swelling can be measured in terms of % weight gain by the 
tablet. The measurement of swelling rate of the floating matrix tablet 
was carried to gain, insight the observed phenomenon of drug release 
with the rates of polymer hydration. Swelling index of the dosage form 
is conducted using USP dissolution apparatus-II in 900 ml of 0.1 N 
hydrochloric acid (HCl) which is maintained at 37±0.5°C, rotated at 
50 rpm. At selected regular intervals, the tablet was withdrawn, and the 
excess water was blotted with tissue paper, and the swelling index was 
calculated using following formula.
% Swelling index = {(Wt) − (W0)/(W0)} × 100
Where, Wt = Weight of the swollen tablet,
W0 = Initial weight of the tablet.
Buoyancy studies
The in vitro buoyancy (floating behavior) [30] of the tablets was 
determined by floating lag time (FLT). The tablets were placed in 
100 ml beaker containing 0.1 N HCl (pH 1.2). The time taken by the 
tablet to reach the surface and float was determined by the FLT [31]. 
The duration of the time the dosage form constantly remained on the 
surface was determined as of total floating time (TFT).
Uniformity of drug content
The drug content was performed to check the dose uniformity in 
the formulation. Randomly 10 tablets were weighed and powdered. 
A quantity equivalent to 100 mg of venlafaxine hydrochloride was 
added into a 100 ml volumetric flask and dissolved in 0.1 N HCI, 
shaken for 10 minutes and made up to the volume with 0.1 N HCl. After 
suitable dilutions, the drug content was determined by ultraviolet (UV) 
spectrophotometer at 224 nm against blank.
In vitro release studies for floating tablets
The release rate of the drug venlafaxine hydrochloride floating 
tablets was determined using USP Type II dissolution apparatus. The 
dissolution was carried out using 900 ml of simulated gastric fluid 
(pH 1.2) as dissolution media, maintained at 37± 0.1°C and rotated 
at 50 rpm for 12 hrs. 5 ml of the samples were withdrawn at suitable 
time intervals, and the samples were replaced with fresh dissolution 
medium [16,32]. The samples were filtered through 0.45 µm membrane 
filter and diluted if necessary. Absorbances of these solutions were 
measured at 224 nm using UV-visible spectrophotometer. Samples 
were assayed in triplicate.
Mechanism of drug release
To analyze the mechanism of drug release rate kinetics from the 
intragastric buoyant tablets, the obtained data were fitted into 
zero order, first order, Higuchi, and Koresmeyer–Peppas release 
model [33-35].
Stability studies
Stability studies of pharmaceutical products were done as per 
ICH guidelines. These studies are designed to increase the rate of 
chemical or physical degradation of the drug substance or product 
using exaggerated storage conditions. The optimized formulation 
was stored at different storage conditions at elevated temperatures 
such as 25°C±2°C/60%±5% RH, 30°C±2°C/65%±5% RH, 
and 40°C±2°C/75%±5% RH for 90 days. The samples were withdrawn 
at intervals of 30 days and checked for physical changes, hardness, 
friability, drug content, FLT, and percentage drug release.
RESULTS AND DISCUSSION
To check the integrity of the drug in the formulation, Fourier transform 
infrared (FTIR) spectra of pure drug venlafaxine hydrochloride, 
Table 1: Composition of floating tablets of venlafaxine hydrochloride average weight of tablets 330 mg
Ingredient’s (mg/tablet) F1 F2 F3 F4 F5 F6 F7 F8 F9
Venlafaxine HCl 75 75 75 75 75 75 75 75 75
Carbopol 934 75 112.5 150 − − − − − −
Xanthan gum − − − 75 112.5 150 − − −
HPMC K100M − − − − − − 75 112.5 150
MCC 95 57.5 20 95 57.5 20 95 57.5 20
Sodium bicarbonate 70 70 70 70 70 70 70 70 70
Magnesium stearate 5 5 5 5 5 5 5 5 5
Talc 10 10 10 10 10 10 10 10 10
HPMC: Hydroxy propyl methyl cellulose, MCC: Micro crystalline cellulose, HCl: Hydrochloric acid
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Carbopol 934, HPMC K100M, xanthan gum, and mixture of drug with 
the above polymers were taken and compared. The FTIR spectrum of 
venlafaxine hydrochloride reveal the presence of peaks at 2939.6 due 
to the presence of C-H stretching, at 1647.2 due to the presence of C=C 
aromatic stretching, at 3349.5 due to the presence of O-H stretching, 
1243.16 due to the presence of C-O stretching, 3349.5 due to the 
presence of N-H stretching, 1308 due to the presence of C-N stretching. 
Major frequencies of functional groups of the pure drug remain intact 
in a powder containing Carbopol 934, HPMC K100M and xanthan gum. 
Hence, there is no major interaction between the drug and polymers 
used in the study.
Pre compression parameters
Floating tablets of venlafaxine hydrochloride were developed to increase 
the gastric residence time of the drug so that they can be retained in the 
stomach for longer time and help in the controlled release of drug up 
to 12 hrs [36]. Different grades of viscosities of the polymers such as 
Carbopol 934, xanthan gum, HPMC K100M are known to be beneficial 
in improving floating property and release characteristics. The pre-
compression parameters obtained for all formulations are tabulated in 
Table 2. The value of the angle of repose indicates good flow property 
of powder blend. Carr’s index value indicates that the powder blend has 
the required flow property for direct compression.
Post compression parameters
The floating tablets were prepared by direct compression method using 
the polymers Carbopol 934, xanthan gum, HPMC K100M to provide 
sufficient drug release retardation and provide sufficient buoyancy to 
the tablets. The results are shown in Table 3. The prepared floating 
tablets were evaluated for thickness, hardness, friability, average 
weight variation, drug content, all the studies were performed in 
triplicates, and the results were expressed in ± standard deviation. The 
hardness for the tablets ensures the good handling characteristics of all 
the batches. The percentage friability was <1% in all the formulations 
ensuring that the tablets were mechanically stable. The weight variation 
for different formulations was found to be in the acceptable limit. The 
drug content uniformity in all the formulations was calculated and the 
presence of the active ingredient was found to be 97.19-98.45%, with 
low standard deviation indicates batch-to-batch consistency.
Swelling index
Swelling index for all the formulations was carried out in the distilled 
water and simulated gastric fluid (0.1 N HCl). It was found that the 
formulation showed rapid uptake of distilled water whereas there 
was gradual constant uptake of simulated gastric fluid (Fig. 1). The 
tablets containing Carbopol 934 and HPMC K100M showed maximum 
swelling in 12 hrs with a sharp increase up to 8 hrs which may be due to 
increased concentration of HPMC K100M which retain water and form 
a thick swollen mass.
Buoyancy studies
The in vitro floating behavior of the tablets was studied by placing 
them in beaker containing 0.1 N HCl (pH 1.2). The gas generating 
agents immediately evolves carbon dioxide in the presence of HCl 
solution generating sufficient porosity which helped the dosage unit 
to float. Formulation F1-F3 prepared with Carbopol 934 started 
floating after 52 seconds and remains buoyant for 10 hrs till they 
were completely eroded. On the other hand, formulation F4-F6 
prepared with xanthan gum which shows a floating time of 8 hrs and 
formulation of F7-F9 prepared with HPMC K100M show decrease in 
FLT to 34 seconds and increased floating duration time to >12 hrs. 
This may be due to the difference in concentration of polymers 
and gas generating agent [37]. This might be due to high viscosity 
polymer HPMC K100M maintains the integrity of the tablets for 
longer duration by reducing the effect of erosion thus resulting in an 
increase in floating time. The results are shown in Table 4. Thus, it 
can be concluded that the batch containing HPMC polymers showed 
good FLT and TFT.
Table 2: Evaluation parameters of powder blend








F1 29°11±0.1 0.36±0.004 0.41±0.018 11.8±0.8
F2 30°31±0.2 0.37±0.001 0.44±0.017 13.4±0.8
F3 32°11±0.5 0.38±0.005 0.44±0.004 13.3±0.6
F4 30°61±0.3 0.35±0.005 0.41±0.003 14.2±1.4
F5 32°81±0.5 0.34±0.004 0.40±0.018 14.8±1.2
F6 33°81±0.1 0.35±0.002 0.42±0.001 16.2±0.7
F7 28°11±0.7 0.35±0.002 0.40±0.005 12.6±0.9
F8 28°51±0.3 0.36±0.003 0.41±0.002 12.7±1.1
F9 31°21±0.1 0.36±0.005 0.42±0.004 14.2±1.3
Table 3: Evaluation parameters of formulations
Formulation Thickness (mm) Hardness (kg/cm2) Friability (%) Weight variation (mg) Drug content (%)
F1 3.76±0.04 5.33±0.02 0.65±0.07 331.2±1.3 98.06±0.002
F2 3.68±0.07 5.61±0.05 0.59±0.09 330.7±1.4 98.39±0.001
F3 3.62±0.02 5.44±0.03 0.53±0.05 331.5±1.7 97.22±0.001
F4 3.71±0.04 5.48±0.01 0.54±0.11 330.2±2.1 99.02±0.001
F5 3.67±0.09 5.86±0.04 0.47±0.08 329.8±2.3 97.18±0.000
F6 3.63±0.11 6.14±0.02 0.47±0.12 331.3±2.1 97.56±0.001
F7 3.74±0.02 5.42±0.03 0.57±0.04 329.2±1.4 97.19±0.002
F8 3.76±0.01 5.57±0.01 0.54±0.07 328.7±1.8 98.45±0.001
F9 3.69±0.05 5.72±0.05 0.53±0.06 331.4±1.2 98.28±0.002
Table 4: Buoyancy studies of formulations










FLT: Floating lag time
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In vitro drug release studies
In vitro drug release studies were carried out using USP dissolution 
apparatus Type II at 50 rpm. The drug release at different time 
intervals was measured using a UV-visible spectrophotometer 
at 224 nm. To check the 100% dissolution release profile, formulations 
were subjected to dissolution studies for 12 hrs. Among the nine 
formulations, F8 was best and shows 98.34% drug release in the end 
of 12 hrs. It is evident from the in vitro dissolution data that increase 
in HPMC K100M concentration decreases the release rate which might 
be due to increase in diffusional path length, which the drug molecule 
may have to travel. It also indicates that higher viscosity of the polymer 
concentrations greatly retard the release of drug. Hence, formulation 
F8 was selected as the optimized formulation. The results are shown 
in Table 5.
Release kinetics
The in vitro drug release data of the floating tablets were evaluated 
kinetically by zero order kinetics; first order kinetics, Higuchi plot, and 
Peppa’s models. The regression coefficient (R2) value for zero order, 
first order, Higuchi’s, and Peppa’s plots for optimized formulation F8 
was found to be 0.959, 0.953, 0.998, 0.987 (Table 6). The optimized 
formulation F8 follows Higuchi’s plot since the regression coefficient 
is 0.998 and were found to be linear, which indicates that the drug 
release depended on the square root of the time and predominantly 
controlled by diffusion process. The mechanism of drug release is 
predicted using Korsmeyer–Peppas equation. The n value of optimized 
formulation F8 is 0.66. This indicates that the drug release depends 
on swelling, diffusion, and erosion. All formulations follow then 
on - Fickian/anomalous type of diffusion.
Stability studies
Stability studies were carried out on selected formulations (F8) as per 
ICH guidelines. There was not much variation in matrix integrity of the 
tablets at all the temperature conditions. There were no significant 
changes in drug content, physical stability, hardness, friability, drug 
release, FLT (Table 7) for the selected formulation F8 after 90 days.
Comparison with marketed product
The marketed product released 96.16% drug in 10 hrs, whereas 
the optimized formulation F8 released 98.3% of drug in 12 hrs. 
Thus, comparative study of the marketed product of venlafaxine 
hydrochloride showed that the optimized formulation F8 has better 
control over release rate when compared with the commercial product 
(Fig. 2).
CONCLUSION
FDDS are retained in the stomach for a longer time and assist in 
improving the oral controlled delivery of drugs that have an absorption 
window in the particular region of the GIT as well as for controlling 
Fig. 1: Comparison of swelling index of all the formulation
Fig. 2: Comparative studies with optimized formulation and 
marketed product
Table 5: Percentage drug release of formulations
Time (hrs) Formulations
F1 F2 F3 F4 F5 F6 F7 F8 F9
1 24.87 22.92 20.06 38.34 33.28 27.54 23.46 22.43 17.84
2 36.24 33.82 29.71 52.15 45.38 38.15 36.87 31.11 24.18
4 58.16 55.27 48.07 81.67 64.19 56.77 57.82 53.67 43.67
6 76.08 71.18 69.18 96.44 81.23 79.26 72.09 65.28 61.08
8 87.28 85.33 78.92 96.94 97.61 96.13 83.12 76.59 69.49
10 94.79 91.67 86.13 97.96 97.92 98.21 94.65 88.76 83.54
12 96.53 93.11 88.33 98.1 98.67 98.72 98.74 98.34 90.03
Table 6: Correlation coefficients of different mathematical 









F1 0.891 0.938 0.961 0.964 0.612
F2 0.912 0.947 0.984 0.972 0.579
F3 0.934 0.979 0.987 0.987 0.586
F4 0.830 0.872 0.857 0.878 0.457
F5 0.886 0.907 0.893 0.885 0.466
F6 0.898 0.926 0.935 0.959 0.569
F7 0.925 0.947 0.990 0.985 0.669
F8 0.959 0.953 0.998 0.987 0.660
F9 0.974 0.958 0.995 0.982 0.716
Table 7: Stability studies of optimized formulation F8
Time (days) 25°C±2°C/60% RH±5% RH, 30°C±2°C/65% 








30 5.56 98.45 98.34 >12
60 5.56 98.42 98.27 >12
90 5.48 98.18 98.71 >12
TFT: Total floating time
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the release of the drug having site-specific absorption limitation. 
Venlafaxine hydrochloride, an antidepressant drug exhibits pH 
dependent solubility. Hence, an attempt was made to develop gastro 
retentive delivery system of venlafaxine hydrochloride which increased 
the bioavailability of venlafaxine hydrochloride and also to reduce the 
frequency of administration, thereby improving patient compliance 
and therapeutic efficacy.
In the present study, formulations F1-F9 were prepared by direct 
compression. The dissolution studies were carried out for 12 hrs. 
When compared to other formulations, F8 showed good FLT and TFT. 
Based on all these results, formulation F8 was selected as the optimized 
formulation and was compared to the marketed product. It was found 
that the optimized formulation F8 has better control over release rate 
in comparison to the commercial product. The drug-polymer ratios, 
viscosity of polymers, were found to influence the drug release and 
floating properties of the prepared tablets. From the results, it can 
be concluded that as the concentration of the polymer increased FLT 
decreased and the percentage drug release was prolonged. Viscosity 
of the polymer also showed a directly proportional relationship with 
swelling characteristics of the tablets. The optimized formulation (F8) 
was subjected for stability studies as per ICH guidelines with no 
significant change in the various evaluated parameters of the 
formulations. Overall, this study concludes that viscosity is a major 
factor affecting the release and floating properties of the gastric 
floating drug delivery system [38]. The use of hydrophobic retardant 
and hydrophilic polymer in combination had its own advantages of 
maintaining integrity and buoyancy of tablets. And also in initial burst 
effect was minimized. It could be concluded that for proper floating 
duration and in vitro release, the hydrophobic retardant and hydrophilic 
polymer must be used in proper ratio [38].
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